27 April 2017
EMA/252355/2017
EMEA/H/C/002272

Public statement

Clopidogrel/Acetylsalicylic acid Teva

Withdrawal of the marketing authorisation in the European Union

On 3 June 2016, the European Commission withdrew the marketing authorisation for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Clopidogrel/Acetylsalicylic acid Teva was granted marketing authorisation in the EU on 1 September 2014 for the prevention of atherothrombotic events.

Clopidogrel/Acetylsalicylic acid Teva is a medicine that contains two active substances, clopidogrel and acetylsalicylic. There are other medicinal products marketed in the EU that contain this combination of substances as well as products containing clopidogrel or acetylsalicylic alone.

The European Public Assessment Report (EPAR) for Clopidogrel/Acetylsalicylic acid Teva will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact